Irinotecan: summary and future directions

Oncology (Williston Park). 2001 Jan;15(1 Suppl 1):46-7.

Author

Affiliation

¹ Division of Hematology and Oncology, Vanderbilt University Medical School, The Vanderbilt Clinic, Nashville, TN 37232-5536, USA. david.johnson@mcmail.vanderbilt

PMID: 11221021

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents, Phytogenic / therapeutic use*
Camptothecin / analogs & derivatives*
Camptothecin / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Small Cell / drug therapy*
Carcinoma, Small Cell / mortality
Combined Modality Therapy
Forecasting
Humans
Irinotecan
Lung Neoplasms / drug therapy*
Survival Analysis
United States

Substances

Antineoplastic Agents, Phytogenic
Irinotecan
Camptothecin